Picture loading failed.

Anti-IL13 therapeutic antibody (Pre-made Lebrikizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a Phase II clinical trial for the treatment of asthma.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-299-1mg 1mg 3090
GMP-Bios-ab-299-10mg 10mg 21890
GMP-Bios-ab-299-100mg 100mg 148000
GMP-Bios-ab-299-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL13 therapeutic antibody (Pre-made Lebrikizumab biosimilar,Whole mAb)
INN Name Lebrikizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure4i77:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesChugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox
Conditions Approvedna
Conditions ActiveAtopic dermatitis
Conditions DiscontinuedAsthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis
Development Techna